Tempus is a digital health company that uses artificial intelligence to provide personalized healthcare solutions. They have built the world’s largest library of clinical and molecular data, starting with cancer.

Main Features:

AI Clinical Assistant: Tempus One, an AI-enabled clinical assistant, is available for all providers. It leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips.

Genomic Profiling: Tempus offers genomic profiling and algorithmic tests to help physicians make more informed treatment decisions.

Clinical Trial Matching: The platform allows for fast, up-to-date clinical trials search using specific criteria.

Digital Pathology: Tempus provides digital pathology services, including Tempus Pixel for therapy response evaluation and specific disease areas like lung, breast, neuro, and cardio.

Sequencing and Data Collaborations: Tempus offers sequencing services and promotes data collaborations for better drug development.

Clinical Research Services: Tempus provides services for clinical trial enrollment and has a platform called Tempus PRO™ for neurology and psychiatry.

EHR Integration: Tempus supports EHR integration for seamless data access and management.

Publications: Tempus regularly publishes research, webinars, and other resources to stay informed about the latest developments in personalized healthcare.

Use Cases:

Providers: Tempus helps physicians make more informed treatment decisions.

Life Sciences: Tempus assists pharmaceutical and biotech companies with better drug development.

Patients: Tempus helps patients find their own unique and optimal therapy options.

Notable Achievements:

Tempus’ xT Platform increases cancer patients’ personalized therapeutic opportunities.

FDA granted Tempus Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.

Tempus launched a standalone RNA next-generation sequencing assay, Tempus xR.

Tempus has partnerships with 90% of the top 20 pharma oncology companies and over 200 biopharma partnerships.

More than 50% of all Academic Medical Centers and oncologists in the US are connected to Tempus.

Tempus has over 6,000,000+ de-identified research records and has identified over 24,000+ patients for potential enrollment into clinical trials in their network.